# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Needham reiterates Verrica Pharmaceuticals (NASDAQ:VRCA) with a Buy and maintains $8 price target.
NCE status provides a minimum of five years of regulatory exclusivity The Company's U.S. patents and pending patent appl...
Needham analyst Serge Belanger reiterates Verrica Pharmaceuticals (NASDAQ:VRCA) with a Buy and maintains $8 price target.
HC Wainwright & Co. analyst Oren Livnat maintains Verrica Pharmaceuticals (NASDAQ:VRCA) with a Buy and raises the price ...
Verrica Pharmaceuticals (NASDAQ:VRCA) reported quarterly losses of $(0.53) per share which met the analyst consensus estimate. ...
Companies Reporting Before The Bell • Frontline (NYSE:FRO) is expected to report quarterly earnings at $0.46 per share on reve...